18 and older, any sex, with Anxiety or Sleep Disturbance. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Worry-related Sleep DisturbancesPrimary· Baseline, 2 months
5 questions from the 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) pertaining to anxiety and sleep will be used to assess worry-related sleep disturbances over the past 7 days. These questions are on a 5-point Likert scale where 1 is "Not at all" and 5 is "Very much". Scores can range from 5 to 25 and higher scores indicate a worse outcome.
Group
Value
95% CI
TAU + App-Delivered Mindfulness Training (MT)
-4
-8.0 – -2.8
Treatment as Usual (TAU)
-1
-4 – 2.0
Change in WorrySecondary· Baseline, 2 months
Penn State Worry Questionnaire (PSWQ) will be used to assess worry. The PSWQ is a 16-item questionnaire that uses a 5-point Likert scale where 1 is "Not at all typical of me" and 5 is "Very typical of me". Scores can range from 16 to 80 and higher scores indicate a worse outcome
Group
Value
95% CI
TAU and App-delivered Mindfulness Training (MT)
-9
-12.2 – -1.0
Treatment as Usual (TAU)
0.0
-4.0 – 2.5
Change in Total Sleep Time (TST)Secondary· Baseline, 2 months
A Fitbit will be used to assess sleep trends over a 1 week period
Group
Value
95% CI
TAU and App-delivered Mindfulness Training (MT)
9
-28 – 34
Treatment as Usual (TAU)
3
-21 – 37
Changes in Non-reactivitySecondary· Baseline, 2 months
Non-reactivity subscale from the 15-item Five Facet Mindfulness Questionnaire (FFMQ) will be used to measure changes in emotional reactivity. This subscale is based on responses to 3 questions measured on a 5-point Likert scale where 1 is "Never or rarely" and 5 is "Very often or always true". Scores can range from 3 to 15 and higher scores indicate a better outcome.
Group
Value
95% CI
TAU + App-Delivered Mindfulness Training (MT)
4.5
1.0 – 6.0
Treatment as Usual (TAU)
0
-2.0 – 2.5
Sponsor's own description
The purpose of this study is to test an app-based mindfulness training program for worry to see if it can help individuals decrease worry and improve sleep.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other trials of App-Delivered Mindfulness Training (MT)
Trials testing the same drug.
NCT06051084 — Investigating How the Brain Processes Different Experiences
· NA
· unknown
NCT06145425 — Testing an Evidence-Based Program for Clinician Burnout
· NA
· completed
NCT05881681 — A Mindfulness Approach to UA for Afro-descendants
· NA
· completed
Other recruiting trials for Anxiety
Currently open trials in the same condition.
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or
· Phase 2
· recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety
· NA
· recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
· NA
· recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years
· NA
· recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect
· recruiting
Other Brown University trials
Trials by the same sponsor.
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g
· Phase 2
· not yet recruiting
NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption
· Phase 2
· recruiting
NCT07398443 — Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults
· NA
· recruiting
NCT05901766 — Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brown University
Last refreshed: 10 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684057.